Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.42 |
| ▸ | FNTB | P49356 | 8/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL6700610 | 0.74 | FNTA (0.48) | FNTAFNTBBTN3A1PGGT1BALOX15 | |
| SCHEMBL28654612 | 0.70 | ALDH1A1 (0.41) | KDM4ETSHR | |
| SCHEMBL6690483 | 0.68 | BTN3A1 (0.54) | FNTAFNTBBTN3A1PGGT1BALOX15 | |
| SCHEMBL22235275 | 0.68 | BTN3A1 (0.54) | FNTAFNTBBTN3A1PGGT1BALOX15 | |
| SCHEMBL7736242 | 0.65 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL25333699 | 0.65 | BTN3A1 (0.36) | BTN3A1TSHR | |
| SCHEMBL4649593 | 0.65 | ALOX15 (0.47) | KDM4ETSHRALOX15 | |
| SCHEMBL6694732 | 0.65 | ALOX15 (0.41) | FNTAFNTBBTN3A1ALOX15 | |
| SCHEMBL3270090 | 0.64 | ALOX15 (0.37) | KDM4ETSHRALOX15 | |
| SCHEMBL394658 | 0.63 | FNTA (0.65) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180813-A1 | 4-Amino acid functionalized-2-pyrophosphatyl-pyranes; direct assay, high throughput screening for enzyme inhibitors; N-acetylglucosaminyltransferase | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-09-16 | — | — | US | disclosed |
| US-6703213-B2 | ENZYME INHIBITOR FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-09 | — | — | US | disclosed |
| US-20020182661-A1 | Substrate analogs for MurG, methods of making same and assays using same | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-12-05 | — | — | US | disclosed |
| EP-1053305-A4 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | UNIV PRINCETON (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6413732-B1 | N-ACETYLGLUCOSAMINYL-URIDINE DIPHOSPHATE (UDP); MONITORING N-ACETYLGLUCOSAMINYL TRANSFERASE INVOLVED IN BACTERIAL CELL WALL BIOSYNTHESIS; ANTIBIOTICS, BACTERICIDES | THE TRUSTEES OF PRINCETON UNIVERSITY | 2002-07-02 | — | — | US | disclosed |
| EP-1053305-A1 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | Princeton University (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038958-A9 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | UNIV PRINCETON (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999038958-A1 | SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME | PRINCETON UNIVERSITY (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180813-A1 | 4-Amino acid functionalized-2-pyrophosphatyl-pyranes; direct assay, high throughput screening for enzyme inhibitors; N-acetylglucosaminyltransferase | DPAGT1, MAGT1, OGT | FNTA 52/4885FNTB 112/4885BTN3A1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.